Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3353644 | 0.81 | TLR7 (0.49) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL2059204 | 0.80 | TLR7 (0.53) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL8113726 | 0.79 | TLR7 (0.52) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL3356873 | 0.76 | TLR7 (0.49) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL23773832 | 0.72 | TLR7 (0.50) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL3353979 | 0.72 | TLR7 (0.49) | TLR7 | |
| Water SCHEMBL3353923 | 0.71 | TLR7 (0.51) | TLR7 | |
| Water SCHEMBL3353920 | 0.71 | TLR7 (0.51) | TLR7 | |
| SCHEMBL9049222 | 0.69 | ADORA2A (0.41) | TLR7PDE4DPOLBADORA2ALMNA | |
| SCHEMBL24245917 | 0.69 | TLR7 (0.54) | TLR7PDE4DPOLBADORA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678918-B2 | Intermediates for imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
| US-7335773-B2 | Intermediates for imidazonaphthyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-06-15 | — | — | US | disclosed |
| US-7038051-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-6949646-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050107421-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6894165-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030212093-A1 | Viricides, antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-11-13 | — | — | US | disclosed |
| US-6638944-B2 | Have urea containing substituent at 1-position; induce biosynthesis of cytokines such as interferon and tumor necrosis factor, exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-6624172-B2 | Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor, and useful as viricides and antitumor agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20030096998-A1 | Imidazonaphtyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20030083500-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6518280-B2 | Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080091010-A1 | Intermediates for imidazonaphthyridines | IFNG, IRF3, MAVS | TLR7 135/4885PDE4D 2349/4885POLB 216/4885 |
| US-20030083500-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20030096998-A1 | Imidazonaphtyridines | IFNG, IRF3, IFNAR1 | TLR7 96/4885PDE4D 1844/4885POLB 503/4885 |
| US-20070167481-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20060128674-A1 | INTERMEDIATES FOR IMIDAZONAPHTHYRIDINES | IFNG, IRF3, MAVS | TLR7 135/4885PDE4D 2349/4885POLB 216/4885 |
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20050288320-A1 | IMIDAZONAPHTHYRIDINES | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20050107421-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | TLR7 109/4885PDE4D 1938/4885POLB 428/4885 |
| US-20030212093-A1 | Viricides, antitumor agents | IFNG, IFNAR1, MAVS | TLR7 116/4885PDE4D 1093/4885POLB 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.